Department of Pathology

Tatiana Oberyszyn, PhD

Professor and Vice Chair

Tatiana Oberyszyn, PhD

Phone:

614-293-9803

E-mail:

Email Dr. Oberyszyn

Office Location:

M202 Starling-Loving Hall

Mailing Address:

129 Hamilton Hall
1645 Neil Ave
Columbus, OH 43210

Biosketch

The research in my laboratory focuses on using the Skh-1 hairless murine preclinical model to understand the development of ultraviolet light induced squamous cell carcinoma of the skin. We design all of our studies taking into consideration the conditions in humans that contribute to the development of this most common cancer. Our murine model provides us with the opportunity to develop and test both preventive and treatment modalities that can then be applied to patients. We actively are testing a number of different topical and oral compounds as well as foods for potential use as chemopreventive and/or chemotherapeutic agents. We have used our mouse model to examine the effects of different therapeutically relevant immunosuppressive drugs, used by solid organ transplant patients, on UVB induced tumor development. Additionally we are examining differences in the skin and immune system of male and female mice in an attempt to understand why men develop three fold more ultraviolet light induced squamous cell carcinomas. We have shown that the increase in SCC development in male skin is not simply due to men spending more time outdoors, but rather that there are biological differences in the skin of males and females. I have 22 years of experience working with murine models studying the role of the inflammatory response in the development of keratinocyte cancers as well as in wound healing. I have been NIH funded continually for the last 18 years, have graduated 8 Ph.D. students and have mentored several postdoctoral fellows, undergraduate, high school and medical students.

Grants

Title: Post-transplant Cutaneous Squamous Cell Carcinoma and Macrophage Migration Inhibitory Factor.

Role: PI

Sponsor: NIH/NCI R21CA198024-01A1

Dates: 4/16/2016-3/31/2018

The major goals of this project are to test the efficacy of a novel topical inhibitor of MIF in preventing and/ or treating UV induced skin tumors in mice immunosuppressed with the therapeutically relevant immunosuppressive drugs Tacrolimus and MMF.

Academic and Medical Appointments

2015-present Professor, with tenure, Department of Pathology, The Ohio State University

2010-present Vice Chair for Academic Affairs, Department of Pathology, The Ohio State University

2009-present Jack C. Geer M.D., Endowed Professorship in Pathology, The Ohio State University

Education and Training

1994-2001 Research Scientist, Department of Molecular Virology, Immunology & Medical Genetics, The Ohio State University

1991-1994 Postdotoral Fellow, Departments of Surgery and Medical Microbiology and Immunology, The Ohio State University

1990-1991 Postdoctoral Fellow, General Surgery, University of Medicine and Dentistry of New Jersey

1986-1990 Ph.D., Rutgers University, New Brunswick, NJ

1980-1985 B.S., St. John's University, Jamaica, NY

Selected Publications

Search in PubMed